Elafibranor
Elafibranor (GFT505) a experimental medication that is being studied and developed by Genfit for the treatment of cardiometabolic diseases including diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD).
Elafibranor is a dual PPARα/δ agonist.
Elifibranor is mainly focused on the treatment of NASH disease.
Clinical studies
Administered to over 800 patients and healthy volunteers to date, Elafibranor has demonstrated :
As of February 2016 GFT505 has completed 8 clinical trials and none are in progress.
Pre-clinical studies
Efficacy on histological NASH parameters (steatosis, inflammation, fibrosis) in animal disease models – anti-fibrotic activities
The absence of safety concern has been confirmed in a full toxicological package up to 2-year carcinogenicity studies and cardiac studies (in mice).
